Literature DB >> 11063424

Preparation and in vitro characterization of gelatin microspheres containing Levodopa for nasal administration.

B Brime1, M P Ballesteros, P Frutos.   

Abstract

Transnasal absorption of pharmaceutical drugs has been recognized as an interesting alternative to the more conventional routes of administration. The aim of this paper was to develop a method of administrating L-dopa following the transnasal route. Gelatin microspheres were prepared by the w/o emulsification solvent extraction technique: the microspheres had a median particle size of 16.2 +/- 4.2 microm and were prepared using a stirring speed of 600 rpm for 5 min at 80 degrees C. The microspheres obtained were spherical and smooth-surfaced, and the microsphere size was inversely proportional to stirring speed (300-700 rpm) and to the percentage of the emulsifier (Tween 85, 1.4-2.7% v/v). L-dopa was incorporated into the microspheres with an efficiency of 65 +/- 6.7%. L-dopa was released from the microspheres, showing an initial fast release rate, followed by a second slower release rate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063424     DOI: 10.1080/02652040050161765

Source DB:  PubMed          Journal:  J Microencapsul        ISSN: 0265-2048            Impact factor:   3.142


  6 in total

Review 1.  Nasal route and drug delivery systems.

Authors:  Selcan Türker; Erten Onur; Yekta Ozer
Journal:  Pharm World Sci       Date:  2004-06

2.  A Comparison of Two Methods for the Preparation Cefquinome-Loaded Gelatin Microspheres for Lung Targeting.

Authors:  Shaoqi Qu; Cunchun Dai; Fenfang Yang; Tingting Huang; Tianli Xu; Li Zhao; Yuwen Li; Zhihui Hao
Journal:  Pharm Res       Date:  2018-02-05       Impact factor: 4.200

Review 3.  Levodopa in the treatment of Parkinson's disease: an old drug still going strong.

Authors:  Werner Poewe; Angelo Antonini; Jan Cm Zijlmans; Pierre R Burkhard; François Vingerhoets
Journal:  Clin Interv Aging       Date:  2010-09-07       Impact factor: 4.458

Review 4.  Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease.

Authors:  Fatma Haddad; Maryam Sawalha; Yahya Khawaja; Anas Najjar; Rafik Karaman
Journal:  Molecules       Date:  2017-12-25       Impact factor: 4.411

Review 5.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577

Review 6.  Antiparkinson prodrugs.

Authors:  Antonio Di Stefano; Piera Sozio; Laura Serafina Cerasa
Journal:  Molecules       Date:  2008-01-16       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.